Loading...
•
Sep 30, 2023
Intra-Cellular Q3 2023 Earnings Report
Intra-Cellular Therapies experienced revenue growth driven by Caplyta sales and raised full year sales guidance.
Key Takeaways
Intra-Cellular Therapies reported a strong third quarter with total revenues increasing to $126.2 million, driven by a 75% increase in Caplyta net product sales to $125.8 million. The company raised its full year 2023 Caplyta net product sales guidance to $460 to $470 million.
Total revenues for Q3 2023 reached $126.2 million, up from $71.9 million in Q3 2022.
Net product sales of CAPLYTA in Q3 2023 were $125.8 million, a 75% increase compared to $71.9 million in the same period last year.
CAPLYTA total prescriptions increased 71% in Q3 2023 compared to the same period in 2022.
Full year 2023 CAPLYTA net product sales guidance was raised to $460 - $470 million.
Forward Guidance
Intra-Cellular Therapies anticipates continued growth and advancement of its pipeline programs.
Positive Outlook
- Full year 2023 CAPLYTA net product sales guidance increased to $460 to $470 million.
- Full year 2023 SG&A expense guidance lowered to $405 to $420 million.
- Full year 2023 R&D expense guidance lowered to $185 to $200 million.
- Topline results from Study 501 are expected in the first quarter of 2024.
- Topline results from Study 502 are expected in the second quarter of 2024.
Challenges Ahead
- There are no guarantees that CAPLYTA will be commercially successful.
- The company may encounter issues, delays or other challenges in commercializing CAPLYTA.
- CAPLYTA's acceptance by patients and physicians may be limited.
- The company's product sales and availability may be limited by challenges associated with supply and manufacturing activities.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...